

# PRECEPTORSHIP PROGRAMME

## Molecular Cancer Biology for Practising Oncologists and Cancer Treatment De-escalation

**ESMO  
PRECEPTORSHIP**

**LUGANO SWITZERLAND  
18-19 MAY 2022**

Multidisciplinary management, standards  
of care and future perspectives.

**Chairs:**

Michiel H. Stribos, Belgium  
Hendrik K. van Halteren, Netherlands

# ESMO PRECEPTORSHIP PROGRAMME MOLECULAR CANCER BIOLOGY FOR PRACTISING ONCOLOGISTS AND CANCER TREATMENT DE-ESCALATION

Multidisciplinary management, standards of care  
and future perspectives

**Lugano, Switzerland**  
**18-19 May 2022**

---

**CO-CHAIRS:** Michiel H. Strijbos, Belgium  
Hendrik K. van Halteren, Netherlands

**SPEAKERS:** Catherine Alix-Panabieres, France  
Jaafar Bennouna, France  
Birute Brasiuniene, Lithuania  
Alberto J. Cunqueiro Tomas, Spain  
Bram De Laere, Belgium  
Piet Dirix, Belgium  
Alice Indini, Italy  
Gabor Liposits, Denmark  
Benedetta Pellegrino, Italy  
Lazar S. Popovic, Serbia  
Christoph Thomssen, Germany  
Radu A. Vidra, Romania

---

## LEARNING OBJECTIVES

- To receive an overview on novel molecular analysis techniques
- To investigate the development of precision medicine in several tumour types
- To learn about state-of-the-art evidence-based de-escalation strategies
- To explore applications to various tumour types

---

## ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



**Wednesday, 18 May 2022**

|                            |   |   |
|----------------------------|---|---|
| <b>09:00-09:15<br/>15'</b> | <b>Welcome and course introduction<br/>Introduction Topic 1: Molecular Biology for Practising Oncologists</b> | <b>Michiel H. Strijbos, BE</b>                  |
| <b>09:15-10:45<br/>90'</b> | <b>SESSION 1<br/>The use of biomarkers in clinical practice</b>   | <b>Chair:<br/>Lazar S. Popovic, RS</b>          |
| 30'                        | Molecular analysis techniques for the practising oncologist   | Bram De Laere, BE                               |
| 15'                        | Discussion  | Faculty   |
| 30'                        | Liquid biopsies: Indications and limitations  | Catherine Alix-Panabieres, FR                   |
| 15'                        | Discussion  | Faculty   |
| <b>10:45-11:15</b>         | <b>Coffee break</b>   |   |
| <b>11:15-12:00<br/>45'</b> | <b>SESSION 2<br/>Biomarkers-driven research</b>   | <b>Chair:<br/>Alice Indini, IT</b>              |
| 30'                        | Biomarkers-driven research  | Lazar S. Popovic, RS                            |
| 15'                        | Discussion  | Faculty   |
| <b>12:00-14:30<br/>90'</b> | <b>SESSION 3<br/>Precision Medicine in Colorectal cancer and in NSCLC</b>                                     | <b>Chair:<br/>Gabor Liposits, DK</b>            |
| 25'                        | State-of-the-art: Treatment decision based on biomarkers in Colorectal cancer                                 | Hendrik K. van Halteren, NL                     |
| 10'                        | Participant clinical case discussion (1x10')  | Faculty   |
| 10'                        | Discussion  | Radu A. Vidra, RO                               |
| <b>12:45-13:45</b>         | <b>Lunch</b>  |   |
| 25'                        | State-of-the-art: Treatment decision based on biomarkers in NSCLC   | Jaafar Bennouna, FR                             |
| 10'                        | Participant clinical case discussion (1x10')  | Faculty   |
| 10'                        | Discussion  | Michiel H. Strijbos, BE                         |
| <b>14:30-15:30<br/>60'</b> | <b>SESSION 4<br/>Melanoma and non Skin cancers</b>  | <b>Chair:<br/>Alberto J. Cunquero Tomas, ES</b> |
| 25'                        | State-of-the-art: Treatment decision based on biomarkers - Molecular biology for melanoma                     | Alice Indini, IT                                |
| 10'                        | Participant clinical case discussion (1x10')  | Faculty   |
| 10'                        | Discussion  | Birute Brasiuniene, LT                          |
| 15'                        | Concluding remarks Topic 1  | Alberto J. Cunquero Tomas, ES                   |
| <b>15:30-16:00</b>         | <b>Coffee break</b>   |   |
| <b>16:00-16:10<br/>10'</b> | <b>Introduction Topic 2: Cancer Treatment De-Escalation</b>   | <b>Radu A. Vidra, RO</b>                        |
| <b>16:10-16:30<br/>20'</b> | <b>SESSION 5<br/>Are we overtreating patients?</b>  | <b>Chair:<br/>Gabor Liposits, DK</b>            |
| 20'                        | Overview of the concept and rationale for treatment de-escalation   | Radu A. Vidra, RO                               |
| <b>16:30-17:20<br/>50'</b> | <b>SESSION 6<br/>Adjuvant Colon and Rectal cancer</b>   | <b>Chair:<br/>Radu A. Vidra, RO</b>             |
| 10'                        | Participant clinical case discussion (1x10')  | Faculty   |
| 30'                        | De-escalation options in the curative setting of Colorectal cancer  | Gabor Liposits, DK                              |
| 10'                        | Discussion  | Hendrik K. van Halteren, NL                     |

|                                  |   |   |
|----------------------------------|---|---|
| <b>17:20-18:10</b><br><b>50'</b> | <b>SESSION 7</b><br><b>Metastatic Colorectal cancer</b>                         | <b>Chair:</b><br><b>Radu A. Vidra, RO</b> |
| 10'                              | Participant clinical case discussion (1x10')                                    | Faculty                                   |
| 30'                              | De-escalation option for mCRC<br>Maintenance, Stop and Go, Oxali-free intervals | Jaafar Bennouna, FR                       |
| 10'                              | Discussion  | Hendrik K. van Halteren, NL               |
| 20:00                            | Dinner  |   |

## Thursday, 19 May 2022

|                                  |   |   |
|----------------------------------|---|---|
| <b>09:00-09:50</b><br><b>50'</b> | <b>SESSION 8</b><br><b>Surgery &amp; radiotherapy in Breast cancer: Conservative Breast surgery</b> | <b>Chair:</b><br><b>Birute Brasiuniene, LT</b>                      |
| 10'                              | Participant clinical case discussion (1x10')  | Faculty   |
| 30'                              | Standards of care & future developments   | Christoph Thomssen, DE  |
| 10'                              | Discussion  | Birute Brasiuniene, LT<br>Christoph Thomssen, DE                    |
| <b>09:50-10:40</b><br><b>50'</b> | <b>SESSION 9</b><br><b>Systemic therapy in Breast cancer</b>  | <b>Chair:</b><br><b>Benedetta Pellegrino, IT</b>                    |
| 10'                              | Participant clinical case discussion (1x10')  | Faculty   |
| 30'                              | De-escalation in Breast cancer  | Lazar S. Popovic, RS  |
| 10'                              | Discussion  | Benedetta Pellegrino, IT  |
| 10:40-11:10                      | Coffee break  |   |
| <b>11:10-12:00</b><br><b>50'</b> | <b>SESSION 10</b><br><b>Prostate cancer</b>   | <b>Chair:</b><br><b>Michiel H. Strijbos, BE</b>                     |
| 10'                              | Participant clinical case discussion (1x10')  | Faculty   |
| 30'                              | Watch and wait<br>Definitive radiation therapy vs surgery   | Piet Dirix, BE  |
| 10'                              | Discussion  | Michiel H. Strijbos, BE<br>Birute Brasiuniene, LT<br>Piet Dirix, BE |
| <b>12:00-12:50</b><br><b>50'</b> | <b>SESSION 11</b><br><b>Bladder cancer</b>  | <b>Chair:</b><br><b>Hendrik K. van Halteren, NL</b>                 |
| 10'                              | Participant clinical case discussion (1x10')  | Faculty   |
| 30'                              | Chemoradiation to avoid cystectomy  | Lazar S. Popovic, RS  |
| 10'                              | Discussion  | Hendrik K. van Halteren, NL<br>Lazar S. Popovic, RS                 |
| <b>12:50-13:00</b><br><b>10'</b> | <b>Conclusion Topic 2</b><br><b>Closing remarks</b>   | <b>Hendrik K. van Halteren, NL</b>                                  |
| 13:00-14:00                      | Lunch   |   |

**Note:** Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion